Latest Breaking News On - Prnewswire cardiff oncology inc - Page 1 : comparemela.com

Cardiff Oncology Announces Publication of Data from Phase 1b study in second-line KRAS-mutated mCRC in Clinical Cancer Research

Cardiff Oncology Announces Publication of Data from Phase 1b study in second-line KRAS-mutated mCRC in Clinical Cancer Research
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesKiki patelRicha kumariJames levineAmerican association for cancer researchTaft communicationsExchange commissionClinical cancer researchGilmartin groupPrnewswire cardiff oncology incCardiff oncology incCardiff oncologyAmerican associationCancer researchAnnual meetingFairooz kabbinavar

Cardiff Oncology To Present At The 35Th Annual Piper Sandler Healthcare Conference

Cardiff Oncology To Present At The 35Th Annual Piper Sandler Healthcare Conference
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesRicha kumariPiper sandlerKiki patelJames levineMark erlanderGilmartin groupTaft communicationsPrnewswire cardiff oncology incCardiff oncology incAnnual piper sandler healthcare conferenceLotte new york palaceCardiff oncologyOncology contact

Cardiff Oncology Announces Positive Clinical Data in Pancreatic Cancer and Small Cell Lung Cancer, including Single-Agent Activity from Onvansertib Monotherapy

Pancreatic Cancer Program - Pancreatic cancer Phase 2 trial of onvansertib + SoC in the second-line setting demonstrated greater efficacy vs. historical controls with ORR of 19% and mPFS of 5.0.

United statesKiki patelMark erlanderJames levineRicha kumariFairooz kabbinavarSmall cell lung cancer programTaft communicationsClinical development planOregon health science universityCardiff oncology incPrnewswire cardiff oncology incExchange commissionGilmartin groupUniversity of pittsburghKnight cancer institute

Cardiff Oncology Announces Positive Clinical Data in Pancreatic Cancer and Small Cell Lung Cancer, including Single-Agent Activity from Onvansertib Monotherapy

Pancreatic Cancer Program - Pancreatic cancer Phase 2 trial of onvansertib + SoC in the second-line setting demonstrated greater efficacy vs. historical.

United statesKiki patelJames levineFairooz kabbinavarMark erlanderRicha kumariGilmartin groupUniversity of pittsburghPancreatic cancer programOregon health science universityCardiff oncology incPrnewswire cardiff oncology incKnight cancer instituteClinical development planSmall cell lung cancer programExchange commission

Cardiff Oncology Reports Second Quarter 2023 Results and Provides Business Update

/PRNewswire/ Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug.

Richa kumariJames levineMark erlanderKiki patelGilmartin groupExchange commissionPfizer global product developmentDana farber cancer institutePrnewswire cardiff oncology incCardiff oncology incMedicine team group lead for breast cancerTaft communicationsCardiff oncologyChief executive officerPfizer igniteVice president